SUBSCRIBE
SUBSCRIBE
News   FDA

New Warnings for Genentech, OSI Pharmaceuticals, Inc. Tarceva Cancer Drug

May 11, 2009 | 
1 min read
Reuters -- New warnings have been added to Genentech Inc and OSI Pharmaceutical Inc's cancer drug Tarceva about reports of skin reactions, eye problems and holes in the digestive tract, U.S. health regulators said on Friday.
FDA Approvals
Genentech, Inc.
MORE ON THIS TOPIC
Man walking on a long wavy path with flag at the end, persistence, determination and ultimate business success - 3D Render
Duchenne muscular dystrophy
Sarepta secures early 2027 FDA decision for Duchenne drugs, pushing past confirmatory fail
July 1, 2026
 · 
2 min read
 · 
Tristan Manalac
Podcast
Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water
July 1, 2026
 · 
2 min read
 · 
Jef Akst
Prohibition sign. Halftone hands cross their fingers in a no entry sign. Refusal, stop gesture. Rejection sign. Warning concept. Newspaper collage
Manufacturing
FDA rejects Unicycive and Sobi filings over contract manufacturing deficiencies
June 30, 2026
 · 
2 min read
 · 
Nick Paul Taylor
New Opportunity, Businessman Walks Up Stairs Finds Exit Big Door
FDA
FDA’s cell and gene therapy head steps down after 1 year
June 30, 2026
 · 
2 min read
 · 
Michael Gibney